Dr. Nara Michaelson MD, MS
@narologist
Followers
2K
Following
6K
Media
207
Statuses
1K
Neurologist/MS specialist @BIDMC @HarvardMed👩🏻⚕️ Fellowship training @MGH @BWH 🧡 Cornell Neuro residency @WCMCNeurology 🧠 MIT Alum👩🏻🎓Dartmouth MD 💊
Brookline, MA
Joined May 2019
Multiple Sclerosis is entering its 2024 ERA – that means new treatments on the horizon and a new changes to the McDonald DIAGNOSTIC CRITERIA! Some of these changes are quite significant – to get everyone up to speed I made this thread!
10
177
1K
Wonderful neurology pearls 🧠
@aszelikovich, @gabifpucci, Jonathan, and I created this infographic on a simple step-by-step method for interpreting a nerve conduction study. I hope you find this helpful! 🤓 Thank you @GreenJournal for publishing it!
0
0
4
All in a day's work as an academic . . . meeting with colleagues and mentors, interviewing residency candidates, giving Grand Rounds, and doing all I can to advance science and patient care #womeninneurology 🧠🧡✅
1
1
8
🧠
0
0
2
Gait monitoring with wearable and depth video are both viable options for objective quantification of gait in people with MS in a clinical setting @MayoClinicNeuro
https://t.co/SdaphEzutl
0
3
5
I'm excited they showed non-inferiority of fenebrutinib to ocrelizumab. Paves the way to an oral treatment with CD20 efficacy, which may appeal to some folks. Also excited that we have another way of demonstrating effect in PPMS. More about proof of concept for me - need results
@narologist The primary endpoint in the FENTREPID (PPMS) study was 12-week composite confirmed disability progression. These dose not seem to be any data on effect size.
0
0
2
We will rebuild . . . MYELIN! 🧡
When MS attacks, it strips away myelin, the protective sheath around nerve cells that allows them to transmit electrical impulses. Now, scientists are working on repairing it, offering hope that one day we not only stop MS, but reverse it. Learn more at: https://t.co/zHFcS04FY1
5
4
36
HUGE Breakthrough in MS! We have been awaiting the results of phase 3 studies of fenebrutinib in relapsing MS and in primary progressive MS. They just announced they met their primary endpoint in terms of reducing relapses and achieving non-inferiority to ocrelizumab in PPMS!🧠
7
8
47
We need to have more breakthroughs in this area. I hope one day we will look back and discuss all the advances made and treatment developed in ALS like we now have with MS
0
0
0
Came across this inspiring story of a young woman diagnosed with ALS in the Brain & Life magazine 🧠 https://t.co/29rPxsUpNH
1
1
2
Is there anything more beautiful than a B cell receptor complex ?
0
0
7
This is such a fantastic video!! You have a gift for explaining complex biology and clinical trial data!! @Brandon_Beaber
A New B-Cell Drug for MS! Obexelimab Explained by Neurologist
1
0
7
Classic finding for trainees to be aware
Wall-Eyed Bilateral Internuclear Ophthalmoplegia (WEBINO): An Early Clue to Multiple Sclerosis | Neurology® Journals https://t.co/7qoHHIU5TZ after a long wait finally got it out @PervinSaniya @NeuroUky @GreenJournal @ContinuumAAN
0
0
2
Medicine is hard but can still be rewarding. . . My professors at MIT were the best at demonstrating the joy of working extremely hard while constantly learning and innovating 💡
0
0
0
We talk a lot about medical education 👩🏻🏫but I think we need to bring back the focus on the joy of learning and teach this to our residents and students 🧠
1
0
2
We will rebuild . . . MYELIN!
🎧 Fresh from #ECTRIMS2025! Dr. Nick Cunniffe (@Cambridge_Uni) joins The ECTRIMS Podcast to unpack the CCMR-Two trial results -- the third study to demonstrate that remyelination is possible in people living with #MS. 🔊 Listen to his conversation with host Brett Drummond of
0
0
5